US Stock Futures Up Ahead Of Earnings
US stock futures rose in early pre-market trade, ahead of earnings from major companies. The Chicago Fed National Activity Index for March will be released at 8:30 a.m. ET, while the Conference Board's index of leading indicators for March will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average surged 24 points to 16,367.00, while the Standard & Poor's 500 index futures gained 2.90 points to 1,860.80. Futures for the Nasdaq 100 index rose 9 points to 3,532.25.
A Peek Into Global Markets
Mostly European markets remained closed on Monday.
Asian markets ended mostly higher today. Japan's Nikkei Stock Average fell 0.03%, China's Shanghai Composite declined 1.52% and India's BSE Sensex rose 0.6%.
Analysts at Nomura upgraded Morgan Stanley (NYSE: MS) from “neutral” to “buy.” The target price for Morgan Stanley has been raised from $33 to $36.
Morgan Stanley's shares closed at $30.76 on Thursday.
- TreeHouse Foods (NYSE: THS) today announced that it will acquire Protenergy Natural Foods, an industry leading developer and manufacturer of premium quality food and beverage products, namely private label broth, soups and gravies. To read the full news, click here.
- Karyopharm Therapeutics (NASDAQ: KPTI) today announced the initiation of its first pediatric clinical study, a Phase 1 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in pediatric patients. To read the full news, click here.
- Emergent BioSolutions (NYSE: EBS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BioThrax® (Anthrax Vaccine Adsorbed) for post-exposure prophylaxis (PEP) of anthrax disease resulting from suspected or confirmed exposure to Bacillus anthracis. To read the full news, click here.
- Perfect World (NASDAQ: PWRD) announced that it has entered into a share purchase agreement to acquire a total of 30,326,005 class A ordinary shares of Shanda Games Limited (NASDAQ: GAME). To read the full news, click here.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.